What is it about?

Immune cells play a central role in preventing the growth of cancer. The immune system comprised of numerous different cell types that can act as either teachers or students of one another. The dendritic cell is one of those teaching immune cells. It has the ability to train other immune cells on what to attack and what to tolerate. Since they occupy this central role, they have been used in numerous approaches in our fight against cancer. Here we cover a new way of increasing the function of dendritic cells and by effect cancer immunotherapy: the use of pharmaceutics. Targeting different enzymes in dendritic cells boosts their capacity to mount potent immune responses against cancer.

Featured Image

Why is it important?

Cancer immunotherapy is now increasing survival against cancer at an unprecedented rate. However, nothing in life is devoid of shortcomings. By using small molecules/drugs that can correct the shortcoming of immunotherapy, we can increase the efficacy of those established methods for a relatively low cost. In the end, what matters is to provide efficient therapies yes, but most important,ly, affordable ones.

Read the Original

This page is a summary of: Pharmacological potentiation of monocyte-derived dendritic cell cancer immunotherapy, Cancer Immunology Immunotherapy, November 2022, Springer Science + Business Media, DOI: 10.1007/s00262-022-03333-y.
You can read the full text:



The following have contributed to this page